Daré Bioscience, Inc. Completes Closing of Regulation A Offering

Key Highlights for Investors

• Completion of Regulation A Offering: On March 16, 2026, Daré Bioscience, Inc. (“Daré”, “we”, “us”, or “our”) announced the successful completion of a closing for its previously announced Regulation A offering.
• Offering Details: The offering consisted of up to 4,854,000 Investor Units, each priced at \$5.00. Each Investor Unit comprises one share of Series A Convertible Preferred Stock and two warrants, each warrant entitling the holder to purchase one share of common stock.
• Units Issued: In this closing, the company issued an aggregate of 43,050 Investor Units.
• Trading Details: Daré Bioscience’s common stock is registered under Section 12(b) of the Exchange Act and trades on the Nasdaq Capital Market under the symbol “DARE”.
• Regulatory Filings: The offering was conducted pursuant to Form 1-A (File No. 024-12688), which was qualified by the SEC on January 5, 2026. The offering circular is dated January 6, 2026.
• Reference to Additional Information: Terms of the Series A Preferred Stock and Investor Warrants were previously disclosed in a Form 8-K filed on January 29, 2026, which is incorporated by reference.

Details That May Be Price Sensitive or Impact Shareholder Value

• Dilution Risk: The issuance of new Series A Convertible Preferred Stock and warrants could lead to dilution of existing shareholders, as conversion and warrant exercises would increase the number of outstanding common shares.
• Unregistered Securities: The securities were sold in an unregistered offering, meaning they may be subject to resale restrictions and may not be immediately tradable by investors, which could affect liquidity and value realization for new holders.
• Potential for Additional Capital Raises: The structure and pricing of the offering indicate the company’s ongoing need for capital. Investors should monitor future equity raises or warrant exercises, which could further impact share value.
• No Indication of Emerging Growth Company Status: Daré Bioscience indicated that it is not an emerging growth company, which means it is subject to full public company reporting requirements and has fewer exemptions from certain regulatory standards. This may affect compliance costs and reporting transparency.
• Price Movements: The announcement and completion of an equity offering, particularly one involving preferred shares and warrants, can be material information. It may impact the market price of DARE shares depending on investor perception of dilution, capital needs, and company growth prospects.

Further Information for Shareholders

• Company Information: Daré Bioscience, Inc. is incorporated in Delaware (State Code: DE) and its filings are available under CIK 0001401914. The company’s SEC file number is 001-36395.
• Contact Information: Address: 3655 Nobel Drive, Suite 260, San Diego, CA 92122. Phone: (858) 926-7655.
• SEC Compliance: The company confirms it is current with SEC reporting obligations and is not a shell company. It also does not claim small business or emerging growth company status as of the filing date.

Conclusion

The closing of this Regulation A offering is a significant capital markets event for Daré Bioscience, Inc. The direct issuance of preferred stock and warrants represents both an opportunity and a risk for shareholders, with the potential for further dilution offset by the capital raised to support company operations or growth initiatives. Shareholders and potential investors should closely monitor future disclosures, warrant exercises, and conversion events, as these may materially affect share value and company fundamentals.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should consult the company’s official filings with the SEC and seek professional advice before making investment decisions. The information above is based on the company’s public disclosures as of the indicated date and may not reflect subsequent developments.

View Dare Bioscience, Inc. Historical chart here